A Study of GensSci098 in Subjects With Graves' Disease

Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Study ID
NCT07286656
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GenSci098 — DRUG
    * Administration: Only one dose of GenSci098 will be given. * Route of Administration: Subcutaneous (injected under the skin). * Dose Levels: • Dose 1 • Dose 2• Dose 3• Dose 4

Study Details

To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease

Key Dates

Start date
Nov 21, 2025
Status verified
Feb 2026
Primary completion
Oct 28, 2026
Completion
Mar 18, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: GenSci098

Primary Outcome Measure

Incidence and severity of adverse events (AEs) (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG]). [ Time Frame: 141 days ]

Central Contacts

Related Studies